The kits and
consumables product segment is expected to maintain its lead in the years to
come. Acknowledging this trend, various market players have invested in the
development of novel kits in order to expand their biopsy kits portfolio. For
instance, in April 2021, Sysmex Europe GmbH, along with Sysmex Inostics GmbH,
introduced Plasma-SeqSensei liquid biopsy research use only (RUO) kits in EMEA.
The tissue biopsies
segment emerged as the dominant type segment in 2020. Shortcomings of liquid
biopsies such as the lack of robust efficacy evaluations and associated high
costs are currently bridged by tissue biopsies. This has made tissue biopsy a
gold-standard procedure in the present diagnostic scenario.
Liquid biopsies are
expected to offer lucrative opportunities in the field of oncology-based personalized
medicine and genomic data analysis. Recognizing the potential of these
tests, the regulatory bodies are actively supporting the commercialization of
these products and increasing the use of these assays in clinics. For instance,
in November 2020, the FoundationOne Liquid CDx test was approved by the U.S. FDA
as a companion diagnostic device for multiple cancers.
The liquid biopsies
segment is expected to expand at an exponential rate in the coming years,
wherein increasing investments and strategic initiatives by companies involved
in biopharmaceutical manufacturing and genomic data analysis are expected to
play a central role. The emerging companies are inclined towards collaborating
with well-established industry participants, including SOPHiA Genetics, QIAGEN
Bioinformatics, Agilent Technologies, and Fabric Genomics. This trend is
further expected to favor the overall market growth.
Key players are
focusing on developing novel biopsy platforms, set to achieve business
expansion, further contributing to the revenue generation in the market. In
March 2021, Quick-Core Auto Biopsy System for biopsy procedure soft tissue
biopsy was launched by IZI Medical Products. This product is fully automated,
which is built based on the company’s proprietary semi-automatic system,
Quick-Core.
Related Press
Release@ Cancer Biopsy Market Report
Cancer Biopsy Market
Report Highlights
- By product, kits
and consumables accounted for the largest revenue share in 2020 and are
anticipated to maintain its lead throughout the forecast period. The
adoption of kits and consumables is expected to increase owing to the
significant transition from tumor to liquid biopsy
- Based on type,
tissue biopsies are still considered to be a mainstay of biopsies and are
largely adopted across various diagnosis applications. Additionally, tumor
biopsy is most adopted for diagnosis on individual levels, along with
monitoring the effects of an ongoing oncology treatment
- North America
held the largest revenue share in 2020 owing to the concentrated pool of
active organizations and cancer foundations. The strong network of
government organizations and private cancer foundations in the U.S. has
made significant contributions to the regional revenue generation capacity
- In terms of
application, breast cancer dominated the global market in 2020 and is
expected to maintain its lead throughout the forecast period. Open
surgical biopsy is considered to be a reference standard for the
evaluation of patients with a suspicious breast lesion. This is attributed
to its proven accuracy in diagnosing breast lesions, further contributing
to the revenue generated by this segment
List of Key Players of Cancer Biopsy Market
·
Qiagen N.V.
·
Illumina, Inc.
·
ANGLE Plc
·
BD (Becton, Dickinson And Company)
·
Myriad Genetics
·
Hologic, Inc.
·
Biocept, Inc.
·
Thermo Fisher Scientific, Inc.
·
Danaher
·
F. Hoffmann-La Roche Ltd.
·
Lucence Diagnostics Pte. Ltd.
·
GRAIL, Inc.
·
Guardant Health
·
Exact Sciences Corporation
·
Freenome Holdings, Inc.
·
Biodesix (Integrated Diagnostics)
·
Oncimmune
·
Epigenomics AG
·
HelioHealth (Laboratory for Advanced Medicine)
·
Genesystems, Inc. (Genesys Biolabs)
·
Chronix Biomedical, Inc.
·
Personal Genome Diagnostics Inc.
·
Natera, Inc.
·
Personalis Inc.
About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment